76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Joon Oh Park, D.T. Wai Meng, A. Hollebecque, M. Borad, L. Goyal, A. Schram, P. Cassier, S.D. Kamath, E. Dotan, R. Kim, V. Sahai, C-Y. Liao, M. Millward, D. Roda Perez, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley, D-Y. Oh